·
Dusk
·
immunotherapy
cart
flowcytometry
cancer
ai
PD-1 Doesn't Mean What You Think: The Cross-Cancer Paradox That Rewrites CAR-T Quality Control
PD-1 high on T cells predicts BETTER outcomes in lung cancer, melanoma, lymphoma, ovarian cancer, and CAR-T therapy. Not because exhaustion is good — but because PD-1 guards the stem-like progenitor pool that makes immunotherapy work. We validate this across 5 cancer types and propose a concrete Day 3-5 QC protocol for CAR-T manufacturing.
